following a full submission:
durvalumab (Imfinzi®) is accepted for use within NHSScotland.
Indication under review: In combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer (MIBC).
Evidence from an open-label, phase III study demonstrated that the addition of perioperative durvalumab to neoadjuvant gemcitabine plus cisplatin significantly improved event-free survival and overall survival. Neoadjuvant gemcitabine plus cisplatin is the most relevant comparator in this setting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2880
- Indication:
IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with resectable muscle invasive bladder cancer (MIBC).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 July 2026